Why the Citadel (CGL) share price is up 41% this week

The Citadel (ASX:CGL) share price has risen 41% this week. It's going like a rocket. 

You’re reading a free article on Rask. Join 4,000+ Australians who get our expert advice, tools, exclusive research and investment recommendations. Get your 30-day trial for $1! Learn more

The Citadel

online pharmacy buy singulair online no prescription

(ASX: CGL) share price has risen 41% this week. It’s going like a rocket.

What is Citadel Group?

Citadel describes itself as a leading software and services company that specialises in secure information management in complex environments. Formed in 2007, its name comes from the idea of being a medieval fortress to defend against invaders.

Citadel’s software helps client management make real-time decisions in health, national security, defence, education and other industries. Citadel now has more than 200 employees and offices in most of Australia’s capital cities.

Technology share valuation explained

The following video explains how to value technology shares using SaaS multiples and popular valuation metrics.

Why is Citadel rocketing?

buy lisinopril online lisinopril online no prescription

Citadel shares, like the market as a whole, have been going up strongly this week.

Just over a week ago, Citadel gave an update to say that whilst the full effect of COVID-19 is uncertain, no significant projects or contracts have been delayed or canceled in this period. It said it manages 42% of Australia’s public pathology data and is working to support health providers to adopt new technology to support COVID-19 testing.

However, the company did say that it has taken measures to reduce operating expenses, manage cashflow and defer non-essential capital projects. Citadel said the Wellbeing acquisition is on track and the dividend will be paid. Wellbeing is a global healthcare software business.

A couple of days ago the software company held an extraordinary general meeting to approve the Wellbeing acquisition which has a 59% market share of radiology of NHS acute trusts in England. The retention rate is over 99% with the average relationship among the top 10 customers being over 12 years. Plus, 70% of revenue is recurring with EBITDA margins of around 40%.

Investors seem to really like the acquisition as shareholders approved the buy. It could be a very good acquisition.

These technology shares could also be good long-term investments:

[ls_content_block id=”18457″ para=”paragraphs”]

Disclosure: at the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.

Psst. I reckon you should check out the webinar below – it’ll help you invest, better.

Are you worried? Or buying?

CSL, Xero, ANZ… the ASX is beaten up

Right now, only brave investors are buying. Is ASX Reporting Season your KEY opportunity to act? Buy, or sell.

This coming Monday night, our two most experienced professional investors, Owen Rask and Leigh Gant, are hosting an exclusive and rare webinar on the what to watch this ASX reporting season. LIVE and free

With over 35 years of combined investing experience, join our Chief Investment Officer and Head of Content for our free Q&A.

We’ll be diving into results from CSL, Pro Medicus (ASX: PME), ANZ Bank and more. It’s absolutely free to join us. Take advantage of this volatility with our free playbook. Simply click here to view the topics.

  • Presented by Owen Rask & Leigh Gant
  • Monday, 16 February   | 7pm AEDT 

A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

How can Rask help you?

About Rask

Learn more about us, our your community and our mission.

Rask investing philosophy

Nearly 15 years later.
It's still a work in progress.

Online investment community

You won't find our investment community on Facebook or Reddit because it's secure, free and available now.

Join 250,000+ podcast listeners

250,000 investors tune into the Rask podcasts every month. Find out why.

Find a financial planner

Australia's financial experts. At your doorstep.

Free finance courses

35,000 students have enrolled in free Rask courses. We're on a mission to 100,000.

Subscribe to Rask's free investor newsletter

53,000 Australian investors subscribe to our Sunday newsletter... and love it! It's free.

$50 million invested

We manage almost $50 million on behalf of Aussies. Discover how you can invest with us.

Better investing starts here.

Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best  insights.

Subscribe to Rask's free investor newsletter

Kick off your week with our pick of podcasts, courses and investing resources to keep your finger on the Rask pulse!

Here you go: A $50,000 per year passive income special report

Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.

Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.